Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

BACKGROUND: Ixabepilone, which stabilizes microtubules, has low susceptibility to drug resistance mediated by P-glycoprotein or βIII-tubulin. MATERIALS AND METHODS: This study was designed to determine the maximum tolerated dose (MTD) of oral ixabepilone when administered every 6 h for three doses,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Kunz, Pamela L., He, Aiwu R., Colevas, A. Dimitrios, Pishvaian, Michael J., Hwang, Jimmy J., Clemens, Pamela L., Messina, Marianne, Kaleta, Remigiusz, Abrahao, Fernanda, Sikic, Branimir I., Marshall, John L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703248/
https://ncbi.nlm.nih.gov/pubmed/22331549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9800-3
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk